In VivoOSE Immunotherapeutics has a broad pipeline, spanning oncologic and immunologic indications, but one of its two lead assets is the anti-interleukin (IL)-7R monoclonal antibody, lusvertikimab. The comp
ScripOSE Immunotherapeutics is developing two late-stage assets in different therapeutic areas, cancer and ulcerative colitis, and has a pipeline of products in earlier development, both independently and
ScripBoehringer Ingelheim GmbH hopes to launch 25 new drugs by 2030, and judging by its performance in the first half of this year, it is certainly putting the effort in. “We are stepping up our investmen
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie To Pay $48m Up Front For Preclin